Principal Investigator: Priscilla E. Pemu, MD

Coordinator: Connie Jones, LPN     

Email:  

Phone: 404-752-1133

IRB Protocol: #(SSU00030712)  - BI-124.29

Start Date: 11/01/2015   End Date: 06/01/2017 

Target Enrollment:  8 Participants 

Sponsor(s): Boehringer Ingelheim Pharmaceuticals, Inc.

Lay Summary:

BI 1245.29 - A research study that will help medical researcher learn whether an investigational drugs called empagliflozin reduces blood sugar in African Americans who have type 2 diabetes. This study requires that you are 18 years or above, have high blood pressure and have an A1C level between7-11. Some participants will receive a placebo and others the actual medication to monitor the effectiveness of the medication.